Docetaxel
Product Code:
CDX-D0371
CDX-D0371
Regulatory Status:
RUO
RUO
Shipping:
AMBIENT
AMBIENT
Storage:
-20°C
-20°C
No additional charges, what you see is what you pay! *
Code | Size | Price |
---|
CDX-D0371-M005 | 5 mg | £48.00 |
Quantity:
CDX-D0371-M025 | 25 mg | £121.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Related Products
- Show All
Further Information
Alternate Names/Synonyms:
Taxotere®; NSC 628503; RP 56976; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
Appearance:
White to off-white powder.
CAS:
114977-28-5
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChiKey:
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
Long Description:
Chemical. CAS: 114977-28-5. Formula: C43H53NO14. MW: 807.88. Synthetic. Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the beta?tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.
MDL:
MFCD00800737
Molecular Formula:
C43H53NO14
Molecular Weight:
807.88
Package Type:
Vial
Product Description:
Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the beta?tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.
Purity:
>97% (HPLC)
SMILES:
CC(C)(OC(N[C@H]([C@H](C(O[C@H]1C[C@@]([C@H]([C@@H]([C@@]2(C([C@@H](C3=C1C)O)=O)C)[C@]4([C@@H](C[C@@H]2O)OC4)OC(C)=O)OC(C5=CC=CC=C5)=O)(C3(C)C)O)=O)O)C6=CC=CC=C6)=O)C
Solubility Chemicals:
Soluble in DMSO or ethanol.
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
Documents
References
(1) M.C. Bissery, et al.; Cancer Res. 51, 4845 (1991) | (2) R. Bruno & G.J. Sanderink; Cancer Surv. 17, 305 (1993) (Review) | (3) K. Gelmon; Lancet 344, 1267 (1994) (Review) | (4) M.E. Trudeau; Can. J. Oncol. 6, 443 (1996) (Review) | (5) I.A. Avramis, et al.; Anticancer Res. 21, 2281 (2001) | (6) M. Aapro & E. Rowinsky; Anticancer Drugs 12, S1 (2001) (Review) | (7) P.B. Cassidy, et al.; Clin. Cancer Res. 8, 846 (2002) | (8) M.S. Si, et al.; Invest. New Drugs 21, 281 (2003) | (9) B. Ramaswamy & S. Puhalla; Drugs Today 42, 265 (2006) (Review) | (10) H. Hernandez-Vargas, et al.; Cell Cycle 6, 780 (2007) (Review) | (11) H. Ching-Hsia, et al.; Toxicol. Sci. 145, 59 (2015)
Related Products
Product Name | Product Code | Supplier | Bromobutide | CDX-B0124 | Chemodex | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Flumetsulam | CDX-F0080 | Chemodex | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Flupyrsulfuron-methyl sodium | CDX-F0083 | Chemodex | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||